Business Wire

FL-KNOWBE4

1.12.2021 14:02:14 CET | Business Wire | Press release

Share
KnowBe4’s Team of Cybersecurity Experts Release Predictions for 2022

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today announced its 2022 cybersecurity predictions from its team of industry experts.

The predicted cybersecurity trends for 2022 include:

  • Nuclear Ransomware 3.0
    A trend that is currently building for the future on the side of the bad actor is that ransomware gangs are morphing into "everything gangs." Instead of just doing ransomware and data exfiltration, they are doing cryptomining, botnet creation, DDoS attacks, etc. The attack gangs of the future will look at every new victim as a pot of gold and try to figure out what to do and in which order to maximize financial value extraction.
  • New Malware Family: Not the Kind You Would Welcome Into Your Home
    A new dangerous and persistent metamorphic malware family called “Tardigrade” is a new strain of Windows malware. It can constantly adapt to avoid detection and was first found targeting the biotech industry, including the infrastructure behind vaccine manufacturing, according to security researchers. This “metamorphic” ability prevents the malware from leaving a consistent signature behind, making it very hard for antivirus programs to spot. It contains the sneaky ability to spread both via phishing emails and USB devices.
  • Virtually Pwned
    Meta, the brand formerly known as Facebook, will entice masses to join the Metaverse. This will spawn a rush to establish dominance in the virtual world. As a result, hackers will also be drawn into this world, and we will see virtual attacks against both individuals and organizations. We will see an explosion of bad things happen to people and resources in the virtual world…virtual looting, virtual theft, account takeovers and more creative criminal exploits.
  • Disinformation Powered by Deep Fakes Will Cause a Political/Financial Circus
    We will see a coordinated disinformation campaign that will rely heavily on deep fakes and manipulated footage to cause a political/financial circus. A deep fake could be used to manipulate a certain political party’s views by stating false opinions, promises or beliefs of a particular candidate. This could cause a chain reaction of certain organizations pulling funds from a political campaign based on statements made by the deep fake.
  • An Attack Against Cryptocurrency Will Hit Real World Economies
    A major cryptocurrency will be attacked, causing billions of dollars in lost value either through direct theft or in value loss. Many individuals and organizations will be severely impacted and it will be referred to as the Black Crypto Day.
  • A Major EU Power Station/Utility Provider Will Be Crippled in a Novel Way Other Than Ransomware
    Most likely somewhere in Eastern Europe, we will see some bad actors cut off your power, your gas and your water. Then as you watch in horror as your phone, tablets and laptop batteries die, they will hand out an olive branch that many will be ready to accept, but at what cost?
  • Someone Will Hack Back the Wrong Bad Actor and Trigger an International Incident
    An overly-eager security researcher will think they have identified the culprit behind a major attack. In an act of retaliation, they will hack back only to discover they did not attribute the attack correctly. This will cause a major international incident and the organization responsible will be placed under extreme scrutiny.
  • The Rise of Dark Economy M&A
    A lot of criminal gangs have become extremely wealthy. In fact, some shady organizations are large enough to be listed on a stock exchange. So, we will see a more formalized dark economy emerge with some M&A activity taking place as some gangs will look to cash-in by selling their organization while others look to grow in capability and reach.
  • When AI Goes Wrong In 2022
    We’ll see the first wave of intelligent attack bots. The future is good threat hunting bots versus bad bots and the best algorithm wins.

“In many ways, it seems as if things are getting worse for cybersecurity professionals who are trying their best to protect their organizations,” said Stu Sjouwerman, CEO, KnowBe4. “But I think we are starting to see more of a focus on the human element, including human behavior, of cybersecurity protection measures. This is a positive shift in direction because people can implement all of the technical tools and controls in the world, but if they do not focus their efforts on the human layer of security, they are going to run into challenges. At the end of the day, a strong security culture is what truly matters and what we will see organizations focused on as we move into 2022.”

The predicted trends were collected from KnowBe4’s global team of security awareness advocates who are experts with decades of experience in the cybersecurity field. For more information on KnowBe4’s team of experts, visit https://www.knowbe4.com/security-awareness-training-advocates .

About KnowBe4

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 44,000 organizations around the globe. Founded by IT and data security specialist, Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud, and other social engineering tactics through a new-school approach to awareness training on security. Kevin Mitnick, an internationally recognized cybersecurity specialist and KnowBe4's Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Tens of thousands of organizations rely on KnowBe4 to mobilize their end users as their last line of defense.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye